68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• patients with confirmed or suspected breast/brain/prostate cancer;
• 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
• signed written consent.
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Zhu, MD,PHD
13611093752@163.com
86+13611093752
Backup
Zhaohui Zhu, MD,PHD
pumch_jacobwong@163.com
86+19800370331
Time Frame
Start Date: 2022-08-16
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 90
Treatments
Experimental: 68Ga-RM26-RGD and 18F-FDG PET/ CT scan
Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 18F-FDG, respectively.
Experimental: 68Ga-RM26-RGD and 68Ga-RM26 PET/ CT scan
Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively.
Experimental: 68Ga-RM26-RGD and 68Ga-RGD PET/ CT scan
Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RGD, respectively.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital